Literature DB >> 8835195

Construction and characterization of a stable full-length macrophage-tropic HIV type 1 molecular clone that directs the production of high titers of progeny virions.

T S Theodore1, G Englund, A Buckler-White, C E Buckler, M A Martin, K W Peden.   

Abstract

Mesh：

Substances：

Year:  1996        PMID： 8835195     DOI： 10.1089/aid.1996.12.191

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN： 0889-2229            Impact factor:   2.205


× No keyword cloud information.
  77 in total

1.  Role for the terminal clasp of HIV-1 gp41 glycoprotein in the initiation of membrane fusion.

Authors:  Chan-Sien Lay; Louise E Ludlow; David Stapleton; Anna K Bellamy-McIntyre; Paul A Ramsland; Heidi E Drummer; Pantelis Poumbourios
Journal:  J Biol Chem       Date:  2011-10-05       Impact factor: 5.157

2.  R5 variants of human immunodeficiency virus type 1 preferentially infect CD62L- CD4+ T cells and are potentially resistant to nucleoside reverse transcriptase inhibitors.

Authors:  Françoise Gondois-Rey; Angelique Biancotto; Marcelo Antonio Fernandez; Lise Bettendroffer; Jana Blazkova; Katerina Trejbalova; Marjorie Pion; Ivan Hirsch
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  HIV-1 Infection Primes Macrophages Through STAT Signaling to Promote Enhanced Inflammation and Viral Replication.

Authors:  K Sofia Appelberg; Mark A Wallet; Jared P Taylor; Melanie N Cash; John W Sleasman; Maureen M Goodenow
Journal:  AIDS Res Hum Retroviruses       Date:  2017-04-12       Impact factor: 2.205

4.  Rev-dependent indicator T cell line.

Authors:  Yuntao Wu; Margaret H Beddall; Jon W Marsh
Journal:  Curr HIV Res       Date:  2007-07       Impact factor: 1.581

Review 5.  HIV-1 Vpu - an ion channel in search of a job.

Authors:  Klaus Strebel
Journal:  Biochim Biophys Acta       Date:  2013-07-03

6.  Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.

Authors:  E J Park; L K Vujcic; R Anand; T S Theodore; G V Quinnan
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

7.  CCL2 mobilizes ALIX to facilitate Gag-p6 mediated HIV-1 virion release.

Authors:  David O Ajasin; Vasudev R Rao; Xuhong Wu; Santhamani Ramasamy; Mario Pujato; Arthur P Ruiz; Andras Fiser; Anne R Bresnick; Ganjam V Kalpana; Vinayaka R Prasad
Journal:  Elife       Date:  2019-06-07       Impact factor: 8.140

8.  Experimental Adaptive Evolution of Simian Immunodeficiency Virus SIVcpz to Pandemic Human Immunodeficiency Virus Type 1 by Using a Humanized Mouse Model.

Authors:  Kei Sato; Naoko Misawa; Junko S Takeuchi; Tomoko Kobayashi; Taisuke Izumi; Hirofumi Aso; Shumpei Nagaoka; Keisuke Yamamoto; Izumi Kimura; Yoriyuki Konno; Yusuke Nakano; Yoshio Koyanagi
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

Review 9.  Human cellular restriction factors that target HIV-1 replication.

Authors:  Klaus Strebel; Jeremy Luban; Kuan-Teh Jeang
Journal:  BMC Med       Date:  2009-09-16       Impact factor: 8.775

10.  GPI-anchored single chain Fv--an effective way to capture transiently-exposed neutralization epitopes on HIV-1 envelope spike.

Authors:  Michael Wen; Reetakshi Arora; Huiqiang Wang; Lihong Liu; Jason T Kimata; Paul Zhou
Journal:  Retrovirology       Date:  2010-10-06       Impact factor: 4.602
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.